Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer

Inclusion Criteria * Histologic confirmation of prostate cancer. (Slides will be obtained for central review) * Clinical stage T2b, T2c, T3a, or T3b disease as defined by the AJCC 4th edition staging manual (see Appendix A) * No evidence of metastatic disease (bone, lymph node or visceral) based on bone scan and computed tomography * Adequate hematologic function * WBC\> 4000/mm3 * platelet count \> 100, 000/mm3 * hematocrit of \> 30% * An ECOG Performance Status of zero or one * Age ≥ 18 * A life expectancy of 5 years or more(excluding possible prostate related causes) Exclusion Criteria : * Prior history of malignancy (except for non-melanoma skin cancer) * Prior systemic therapy * No prior chemotherapy * No prior hormonal therapy other than that recommended in this protocol * Prior pelvic radiotherapy * Medical problems (such as an abnormal bleeding propensity) which would make transrectal ultrasound-directed transperineal thermal probe placement hazardous. * Patients with severe insulin-dependent diabetes mellitus and evidence of neuropathy or vaculopathy * Patients with unstable cardiac status including: * Unstable angina pectoris on medication * Patients with documented myocardial infarction within six months of protocol entry * Congestive heart failure requiring medication * Patients on anti-arrhythmic drugs * Severe hypertension (diastolic BP\> 100 on medication * Patients with cardiac pacemakers * Severe cerebrovascular disease (multiple CVA or CVA within 6 months) * Severe COPD (medication requiring, with FEV 1 \< 50% of expected or \< 1 liter) * Individuals who appear unlikely to tolerate the required prolonged stationary position during treatment due to emotional immaturity or instability or otherwise due to mental incompetence.